A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure
New England Journal of MedicinePublished 1 August 1991Open access
Jay N. Cohn, Gary R. Johnson, Susan Ziesche, Frederick R. Cobb, Gary S. Francis, Felix E. Tristani
Citations2,836
SJR quartileQ1
SJR score19.08
SNIP13.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The different effects of the two regimens (enalapril and hydralazine-isosorbide dinitrate) on mortality and physiologic end points suggest that the profile of effects might be enhanced if the regimens were used in combination.
Abstract
The similar two-year mortality in the hydralazine-isosorbide dinitrate arms in our previous Vasodilator-Heart Failure Trial (26 percent) and in the present trial (25 percent), as compared with that in the placebo arm in the previous trial, (34 percent) and the further survival benefit with enalapril in the present trial (18 percent) strengthen the conclusion that vasodilator therapy should be included in the standard treatment for heart failure. The different effects of the two regimens (enalapril and hydralazine-isosorbide dinitrate) on mortality and physiologic end points suggest that the profile of effects might be enhanced if the regimens were used in combination.
Keywords
Medicine
Journal of the Royal Statistical Society Series B (Statistical Methodology)Regression Models and Life-Tables
39,259 Citations1972D. R. Cox
British Journal of CancerDesign and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
8,392 Citations1977Richard Peto, M. C. Pike +8 more
Efficient methods of analysis of randomized clinical trials in which the authors wish to compare the duration of survival among different groups of patients are described.
New England Journal of MedicineEffects of Enalapril on Mortality in Severe Congestive Heart Failure
5,077 Citations1987The Consensus Trial Study Group*
It is concluded that the addition of enalapril to conventional therapy in patients with severe congestive heart failure can reduce mortality and improve symptoms and a significant improvement in NYHA classification was observed in the enAlapril group.
BiometricsA Multiple Testing Procedure for Clinical Trials
3,349 Citations1979Peter C. O’Brien, Thomas R. Fleming
The overall size of the procedure is shown to be controlled with virtually the same accuracy as the single sample chi-square test based on N(m1 + m2) observations and the power is found to bevirtually the same.
New England Journal of MedicineEffect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
2,413 Citations1986Jay N. Cohn, Donald Archibald +16 more
The data suggest that the addition of hydralazine and isosorbide dinitrate to the therapeutic regimen of digoxin and diuretics in patients with chronic congestive heart failure can have a favorable effect on left ventricular function and mortality.
Journal of the American College of CardiologyA placebo-controlled trial of captopril in refractory chronic congestive heart failure
589 Citations1983
It was concluded that captopril is an effective adjunctive treatment to digitalis and diuretic drugs for patients with refractory heart failure.
New England Journal of MedicineVasodilator Therapy of Cardiac Failure
483 Citations1977Jay N. Cohn, Joseph A. Franciosa
The symptoms of cardiac failure are related to some combination of circulatory congestion and low cardiac output and therapy for cardiac failure has traditionally involved the Administration of an inotropic drug to increase the contractile force of the heart and the administration of a diuretic to increasing the renal excretion of salt and water.
Progress in Cardiovascular DiseasesThe role of vasodilator therapy in heart failure
316 Citations1977Kanu Chatterjee, William W. Parmley
The current status of the therapeutic use of vasodilator drugs in acute and chronic heart failure and it is probable that such drugs will emerge and become at least as important as the routine use of digitalis in such patients.
CirculationImproved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure.
294 Citations1983C V Leier, Patricia Huss +2 more
The American Journal of CardiologyStudies of Left Ventricular Dysfunction (SOLVD)—Rationale, design and methods: Two trials that evaluate the effect of enalapril in patients with reduced ejection fraction
186 Citations1990The SOLVD Investigators
The rationale and design of a tiered approach to clinical trials that are large enough to provide reliable information on mortality and morbidity, yet provide relevant information on other endpoints are described.
The American Journal of MedicineContrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure
180 Citations1980Joseph A. Franciosa, Steven R. Goldsmith +1 more
Exercise duration and maximal oxygen uptake in patients with heart failure are not suddenly increased after the administration of hemodynamically effective doses of a vasodilator, but they are increased after long-term treatment with these drugs.
CHEST JournalCombined Oral Hydralazine-Nitrate Therapy in Left Ventricular Failure
137 Citations1978Gordon L. Pierpont, Jay N. Cohn +1 more
Compared the hemodynamic effects of combined oral therapy with hydralazine and isosorbide dinitrate to the effects of intravenous therapy with sodium nitroprusside in 15 patients with congestive heart failure due to cardiomyopathy, all changes were significant.
Journal of the American College of CardiologyAcute and long-term effects of enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure
131 Citations1985Mark A. Creager, Barry M. Massie +7 more
CirculationHemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure.
123 Citations1984T. Barry Levine, M. T. Olivari +3 more
Repeat hemodynamic evaluation in six patients after long-term enalapril therapy showed a persistent effect with significant reductions in right atrial pressure and in mean arterial pressure and a significant increase in cardiac index.
CirculationCurrent therapy of the failing heart.
95 Citations1988J. N. Cohn
Judicious use of vasodilators, diuretics, digoxin, dietary therapy, and exercise therapy can relieve symptoms and improve the quality of life in most patients suffering from this syndrome.
The American Journal of CardiologyClinical and hemodynamic experience with enalapril in congestive heart failure
45 Citations1985Robert Cody
During long-term therapy, enalapril was associated with improved symptomatology, increase of treadmill exercise duration and sustained hemodynamic improvement, and the magnitude of the short-term response was comparable for both preparations.
The American Journal of CardiologyComparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy
36 Citations1986Milton Packer, Norman Medina +1 more
The findings indicate that the choice of 1 vasodilator drug over another in patients with congestive heart failure should be based on studies that compare their long-term rather than short-term hemodynamic and clinical effects.
American Heart JournalHeart failure management: The impact of drug therapy on survival
13 Citations1988Gary S. Francis
Measuring efficacy of drug therapy in patients with heart failure has largely relied on acute and short-term hemodynamic responses, changes in exercise tolerance, and subjective assessment of functional class, which has proved to be more complicated than originally envisioned.